

Report from the Nordic Urothelial Cancer Group

Collaboration Group for Urothelial Cancer under NUF

The group has the intention of two annual meetings - one in the Spring as a one day meeting and one more extensive two-day meeting in the Autumn each year. This strategy has previously been very fruitful and relevant as the research initiatives are increasing regarding multinational studies in urothelial cancer in the Nordic countries. However, because of the virus-pandemic, this strategy has been slightly on hold with only 2 annual status web-meetings in 2020 and 2021. We therefore look very much forward to the physical meeting planned in connection with the congress in Helsinki!

Because of the general situation and the lack of physical meetings, the activity has been restricted to keep each other informed without the usual very constructive networking and mutual inspiration at meetings. However, the research portfolio of the group – organized through NORTH-REG – has been able to initiate and coordinate both the prospective registration study on cystectomy patients (NorCys) as well as an investigator initiated trial on side effects of BCG (The DwellTime Study). Moreover, a Nordic RCT on “en bloc” TURB is in the final stage of preparation and has already been initiated in some Danish sites.

The future therefore looks promising when the world opens for focus on urological cancer and not only less interesting infectious corona diseases.

Jørgen Bjerggaard Jensen, Chairman